Literature DB >> 3315279

Towards an assessment of toxicity in the treatment of ovarian cancer.

L Dones1, E Wiltshaw, B G Birkhead, R R Jackson.   

Abstract

Using data from a randomised clinical trial of two platinum drugs at The Royal Marsden Hospital, London, a descriptive model of toxicity has been developed and tested. Toxicity manifests itself in reducing the effectiveness of different body processes; five were selected in this study as being most critical. The model summarises and combines data from these five sites in terms of a clinician's assessment of the associated risk to the patient. It is hoped that the approach will help clarify toxicity information for use in patient management decision-making and in the reporting of clinical trial results.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315279     DOI: 10.1007/BF00570488

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  1 in total

1.  Ovarian trials at the Royal Marsden.

Authors:  E Wiltshaw
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

  1 in total
  1 in total

1.  Carboplatin is ototoxic.

Authors:  I C Kennedy; B M Fitzharris; B M Colls; C H Atkinson
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.